Geron Corp (GERN) Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat

Go back to Geron Corp (GERN) Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat
Geron Corp (NASDAQ: GERN) Delayed: 1.57 --0 (-0%)
Previous Close $1.57    52 Week High $5.30 
Open $1.57    52 Week Low $1.81 
Day High $1.57    P/E N/A 
Day Low $1.57    EPS $-0.35 
Volume 2,380